Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCAR02 in Refractory Autoimmune Diseases
NCT06503224Phase 1Recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SCAR02 in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjogren's syndrome and 1 more, sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Adverse events up to 2 years. Started Apr 2024; status: recruiting.
02
Drugs
SCAR02
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)Sjogren's syndromesystemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06503224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06503224.